MeSH term
Frequency | Condition_Probility | Female | 201 | 0.0 |
Humans | 317 | 0.0 |
Pregnancy | 2 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Adult | 139 | 0.0 |
Antipsychotic Agents/therapeutic use | 2 | 6.0 |
Comparative Study | 47 | 0.0 |
Genotype | 117 | 1.0 |
Male | 213 | 0.0 |
Middle Aged | 122 | 0.0 |
Receptors, Dopamine/*genetics | 27 | 39.0 |
Catechol O-Methyltransferase/*genetics | 2 | 2.0 |
Monoamine Oxidase/*genetics | 4 | 5.0 |
Mood Disorders/*genetics | 4 | 25.0 |
*Polymorphism, Genetic | 46 | 1.0 |
Receptor, Serotonin, 5-HT2A | 3 | 7.0 |
Receptors, Dopamine D2/*genetics | 185 | 50.0 |
Receptors, Serotonin/*genetics | 2 | 2.0 |
Research Support, Non-U.S. Gov't | 192 | 0.0 |
Intelligence/*genetics | 4 | 26.0 |
Receptors, Dopamine D2/*genetics/physiology | 5 | 41.0 |
Aged | 53 | 0.0 |
Antipsychotic Agents/*adverse effects | 4 | 21.0 |
DNA/genetics | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Schizophrenic Psychology | 2 | 5.0 |
Analysis of Variance | 8 | 0.0 |
Australia | 3 | 1.0 |
Polymorphism, Genetic/*genetics | 35 | 2.0 |
Questionnaires | 3 | 0.0 |
Severity of Illness Index | 6 | 0.0 |
Asian Continental Ancestry Group/*genetics | 5 | 1.0 |
China | 4 | 0.0 |
Gene Frequency | 40 | 0.0 |
Case-Control Studies | 27 | 0.0 |
Obesity/complications/*genetics | 3 | 37.0 |
Polymorphism, Restriction Fragment Length | 33 | 1.0 |
*Genetic Predisposition to Disease | 7 | 0.0 |
Risk Factors | 24 | 0.0 |
Smoking/*genetics | 8 | 19.0 |
Alleles | 115 | 1.0 |
Bipolar Disorder/*genetics | 14 | 12.0 |
Microsatellite Repeats | 3 | 0.0 |
Odds Ratio | 9 | 0.0 |
Polymorphism, Genetic | 44 | 0.0 |
Adolescent | 39 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Genetic Predisposition to Disease | 17 | 0.0 |
Genetic Screening | 4 | 0.0 |
*Mutation | 2 | 0.0 |
Polymerase Chain Reaction | 42 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 96 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Variation (Genetics) | 11 | 0.0 |
Alcoholism/*genetics | 35 | 38.0 |
Continental Population Groups | 3 | 1.0 |
*Membrane Glycoproteins | 14 | 1.0 |
Membrane Transport Proteins/*genetics | 4 | 6.0 |
Minisatellite Repeats | 3 | 2.0 |
*Nerve Tissue Proteins | 16 | 3.0 |
Oceanic Ancestry Group/*genetics | 2 | 8.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Reference Values | 11 | 0.0 |
English Abstract | 11 | 0.0 |
Gene Expression/genetics | 3 | 1.0 |
Gene Frequency/genetics | 21 | 4.0 |
Prevalence | 8 | 0.0 |
Receptors, Dopamine D2/*genetics/*metabolism | 5 | 100.0 |
Arousal/genetics | 2 | 50.0 |
Personality/*genetics | 3 | 10.0 |
Personality Inventory | 3 | 8.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Gene Expression/*genetics | 8 | 7.0 |
Dopamine Antagonists/therapeutic use | 2 | 66.0 |
Exons/*genetics | 2 | 0.0 |
Point Mutation/genetics | 3 | 1.0 |
Treatment Outcome | 6 | 0.0 |
Genetic Markers | 15 | 0.0 |
Risk | 3 | 0.0 |
Alcoholism/*genetics/rehabilitation | 2 | 100.0 |
Aldehyde Dehydrogenase/*genetics | 3 | 1.0 |
*Alleles | 23 | 1.0 |
Genetics, Population | 7 | 1.0 |
Japan | 12 | 0.0 |
Antipsychotic Agents/*therapeutic use | 2 | 6.0 |
Clinical Trials | 2 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Neurotransmitters/*genetics | 3 | 60.0 |
Receptors, Dopamine/genetics | 6 | 50.0 |
Receptors, Serotonin/genetics | 4 | 21.0 |
Schizophrenia/*drug therapy/*genetics | 3 | 23.0 |
Homozygote | 10 | 0.0 |
Sweden/epidemiology | 2 | 1.0 |
Carrier Proteins/*genetics | 9 | 0.0 |
Membrane Glycoproteins/genetics | 6 | 3.0 |
*Membrane Transport Proteins | 16 | 2.0 |
Schizophrenia/*genetics | 21 | 9.0 |
Child | 23 | 0.0 |
Family | 7 | 1.0 |
Linkage Disequilibrium/*genetics | 2 | 2.0 |
Mental Disorders/*genetics | 3 | 15.0 |
Regression Analysis | 5 | 0.0 |
Sex Characteristics | 5 | 0.0 |
Comorbidity | 7 | 2.0 |
Aged, 80 and over | 9 | 0.0 |
DNA Primers | 11 | 0.0 |
European Continental Ancestry Group | 3 | 0.0 |
Great Britain | 2 | 0.0 |
Linkage Disequilibrium | 17 | 2.0 |
Migraine/*genetics | 2 | 15.0 |
Parkinson Disease/*genetics | 5 | 6.0 |
Antipsychotic Agents/blood/*therapeutic use | 2 | 66.0 |
Dopamine Antagonists/blood/*therapeutic use | 2 | 100.0 |
Psychiatric Status Rating Scales | 10 | 4.0 |
Schizophrenia/*drug therapy | 4 | 12.0 |
Taq Polymerase | 9 | 24.0 |
Alcohol Dehydrogenase/*genetics | 4 | 4.0 |
Membrane Glycoproteins/*genetics | 6 | 1.0 |
Mexican Americans/*genetics | 3 | 12.0 |
Mutagenesis, Insertional | 2 | 0.0 |
Nerve Tissue Proteins/*genetics | 3 | 0.0 |
Alcoholism/*genetics/metabolism/psychology | 2 | 100.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Deoxyribonucleases, Type II Site-Specific/genetics | 4 | 9.0 |
Sex Factors | 12 | 0.0 |
Alcoholism/genetics | 4 | 16.0 |
Behavior, Addictive/*genetics | 3 | 100.0 |
Biological Markers | 3 | 0.0 |
Smoking/genetics | 2 | 10.0 |
Substance-Related Disorders/genetics | 4 | 44.0 |
Gene Expression | 3 | 0.0 |
Haplotypes/*genetics | 4 | 2.0 |
Polymorphism, Genetic/genetics | 11 | 1.0 |
Receptors, Dopamine D2/genetics | 19 | 38.0 |
Alcoholism/*genetics/psychology | 6 | 60.0 |
Cross-Sectional Studies | 2 | 0.0 |
Taq Polymerase/*genetics | 4 | 100.0 |
Amino Acid Sequence | 9 | 0.0 |
Animals | 15 | 0.0 |
Molecular Sequence Data | 28 | 0.0 |
Gene Deletion | 4 | 0.0 |
Haplotypes | 18 | 0.0 |
Models, Statistical | 2 | 1.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 4 | 2.0 |
*Methamphetamine | 2 | 100.0 |
*Polymorphism, Restriction Fragment Length | 11 | 1.0 |
Substance-Related Disorders/*genetics | 5 | 31.0 |
Heterozygote | 5 | 0.0 |
Indians, North American/genetics | 2 | 5.0 |
Dopamine/metabolism | 4 | 3.0 |
Intelligence Tests | 2 | 3.0 |
Phenotype | 20 | 0.0 |
Alcoholism/epidemiology/*genetics | 3 | 30.0 |
Receptors, GABA-A/*genetics | 5 | 6.0 |
Social Environment | 2 | 11.0 |
Variation (Genetics)/*genetics | 5 | 2.0 |
Carrier Proteins/genetics | 7 | 1.0 |
Italy | 5 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Alcoholism/*complications/*genetics | 2 | 66.0 |
Deoxyribonucleases, Type II Site-Specific | 6 | 2.0 |
Schizophrenia/drug therapy/*genetics | 3 | 18.0 |
Exploratory Behavior | 2 | 22.0 |
Apolipoproteins E/*genetics | 2 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
Recurrence/prevention & control | 2 | 5.0 |
Alcoholism/*genetics/physiopathology | 2 | 66.0 |
Event-Related Potentials, P300/*genetics | 2 | 100.0 |
Family Health | 4 | 0.0 |
Linkage (Genetics) | 25 | 0.0 |
Lod Score | 8 | 0.0 |
Environment | 2 | 2.0 |
Personality/genetics | 2 | 28.0 |
Chi-Square Distribution | 16 | 2.0 |
Chromosomes, Human, Pair 11/*genetics | 4 | 1.0 |
*Genetics, Population | 2 | 0.0 |
Body Mass Index | 6 | 0.0 |
Indians, North American/*genetics | 2 | 2.0 |
Longitudinal Studies | 3 | 0.0 |
Obesity/*genetics | 3 | 2.0 |
Dopamine/physiology | 2 | 3.0 |
Dopamine beta-Hydroxylase/*genetics | 3 | 6.0 |
Cloning, Molecular | 6 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Pedigree | 19 | 0.0 |
Phylogeny | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Risk Assessment | 3 | 0.0 |
*Heterozygote | 4 | 1.0 |
Models, Genetic | 16 | 0.0 |
Introns/genetics | 4 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Catechol O-Methyltransferase/genetics | 3 | 10.0 |
Isoenzymes/genetics | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Age of Onset | 8 | 0.0 |
Child, Preschool | 5 | 0.0 |
Cytoskeletal Proteins/*genetics | 2 | 1.0 |
DNA Mutational Analysis | 8 | 0.0 |
Myoclonus/*genetics | 3 | 33.0 |
Sarcoglycans | 2 | 8.0 |
*Variation (Genetics) | 7 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Alcoholism/diagnosis/*genetics | 2 | 40.0 |
Genetic Predisposition to Disease/*genetics | 4 | 1.0 |
Amino Acid Substitution | 2 | 0.0 |
Bipolar Disorder/genetics | 2 | 9.0 |
Cysteine | 6 | 5.0 |
Depressive Disorder/genetics | 3 | 23.0 |
Psychotic Disorders/*genetics/psychology | 2 | 50.0 |
Schizophrenia/genetics | 4 | 15.0 |
Serine | 6 | 6.0 |
Brain/metabolism | 2 | 0.0 |
Obesity/genetics | 2 | 3.0 |
Receptors, Dopamine D2/*genetics/metabolism | 4 | 50.0 |
Membrane Transport Proteins/genetics | 4 | 12.0 |
Nerve Tissue Proteins/genetics | 5 | 1.0 |
Dopamine/genetics | 2 | 40.0 |
Serotonin/genetics | 2 | 25.0 |
*Chromosome Mapping | 4 | 0.0 |
Mice | 4 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 21 | 0.0 |
Attention Deficit Disorder with Hyperactivity/genetics | 2 | 28.0 |
*Linkage Disequilibrium | 7 | 4.0 |
*Logistic Models | 2 | 22.0 |
Statistics | 3 | 0.0 |
Body Height/*genetics | 2 | 7.0 |
Cholesterol/blood | 2 | 0.0 |
Nuclear Family | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
DNA/analysis | 6 | 0.0 |
Dystonia/*genetics | 3 | 13.0 |
Linkage (Genetics)/genetics | 5 | 1.0 |
Chromosome Mapping | 30 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Linkage Disequilibrium/genetics | 4 | 2.0 |
Prospective Studies | 5 | 0.0 |
Age Factors | 6 | 0.0 |
*Linkage (Genetics) | 13 | 1.0 |
African Continental Ancestry Group/genetics | 4 | 1.0 |
European Continental Ancestry Group/genetics | 11 | 1.0 |
Smoking/epidemiology/*genetics | 2 | 40.0 |
Attention Deficit Disorder with Hyperactivity/*genetics | 3 | 6.0 |
Brain Chemistry/genetics | 2 | 4.0 |
*Family Health | 2 | 3.0 |
Dopamine/*genetics | 5 | 38.0 |
Dopamine beta-Hydroxylase/genetics | 2 | 7.0 |
Spain/epidemiology | 2 | 1.0 |
Blotting, Southern | 5 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Hybrid Cells/cytology | 2 | 6.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Karyotyping | 2 | 0.0 |
Parents | 2 | 2.0 |
European Continental Ancestry Group/*genetics | 8 | 2.0 |
Repetitive Sequences, Nucleic Acid/genetics | 5 | 5.0 |
Double-Blind Method | 3 | 0.0 |
Placebos | 2 | 0.0 |
Introns | 4 | 0.0 |
Tomography, Emission-Computed | 2 | 1.0 |
Autistic Disorder/genetics | 2 | 14.0 |
*Chromosomes, Human, Pair 11 | 21 | 3.0 |
Base Sequence | 24 | 0.0 |
Corpus Striatum/*metabolism | 2 | 10.0 |
*DNA Methylation | 2 | 0.0 |
Lymphocytes/metabolism | 2 | 0.0 |
*Gene Frequency | 3 | 0.0 |
Taiwan/epidemiology | 2 | 1.0 |
*Mutation, Missense | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Hamsters | 2 | 0.0 |
China/ethnology | 2 | 1.0 |
Data Collection | 2 | 2.0 |
Ethnic Groups/genetics | 2 | 1.0 |
Receptors, Dopamine D1/*genetics | 2 | 7.0 |
Gene Dosage | 2 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
Evolution | 2 | 0.0 |
*Genome, Human | 2 | 0.0 |
Europe/ethnology | 2 | 2.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
*Chromosome Deletion | 2 | 0.0 |
Behavior, Addictive/genetics | 2 | 50.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Mutation | 7 | 0.0 |
Dopamine/*physiology | 3 | 3.0 |
Reward | 5 | 14.0 |
*Schizophrenic Psychology | 3 | 4.0 |
Bupropion/*therapeutic use | 2 | 100.0 |
Smoking Cessation/ethnology/*methods | 2 | 100.0 |
Twin Studies | 2 | 11.0 |
gamma-Aminobutyric Acid/*physiology | 2 | 13.0 |
Restriction Mapping | 5 | 0.0 |
Glycine/genetics | 2 | 2.0 |
Serine/genetics | 2 | 2.0 |
Deoxyribonucleases, Type II Site-Specific/*genetics | 4 | 12.0 |
Genome | 2 | 0.0 |
Exons | 10 | 0.0 |
Tourette Syndrome/*genetics | 3 | 17.0 |
Gene Expression Regulation | 2 | 0.0 |
Receptors, Dopamine D2/*genetics/*physiology | 2 | 100.0 |
Quebec | 2 | 3.0 |
Haplotypes/genetics | 4 | 0.0 |
Taiwan | 3 | 1.0 |
*Haplotypes | 5 | 2.0 |
Child of Impaired Parents/*psychology | 2 | 50.0 |
Event-Related Potentials, P300/genetics | 2 | 66.0 |
Orientation | 2 | 40.0 |
Psychomotor Performance | 2 | 6.0 |
Dopamine/*metabolism | 2 | 1.0 |
Tyrosine 3-Monooxygenase/*genetics | 5 | 3.0 |
Mental Disorders/genetics | 2 | 14.0 |
Cell Line | 2 | 0.0 |
Spiperone/analogs & derivatives/metabolism | 2 | 100.0 |
*Cocaine | 2 | 33.0 |
Genetic Markers/*genetics | 3 | 2.0 |
Substance-Related Disorders/*genetics/psychology | 2 | 66.0 |
DNA-Directed DNA Polymerase | 2 | 7.0 |
Recurrence | 2 | 0.0 |
Alcoholism/genetics/psychology | 2 | 66.0 |
Heterozygote Detection | 4 | 0.0 |
United States | 2 | 0.0 |
Schizophrenia/epidemiology/*genetics | 2 | 9.0 |
Diagnostic and Statistical Manual of Mental Disorders | 2 | 8.0 |
Schizophrenia/diagnosis/*genetics | 3 | 20.0 |
Alcoholism/ethnology/*genetics | 2 | 22.0 |
Alcoholism/diagnosis/*genetics/rehabilitation | 2 | 100.0 |
*Gene Deletion | 2 | 0.0 |
Linkage (Genetics)/*genetics | 6 | 2.0 |
Serotonin/*genetics | 2 | 22.0 |
*Genotype | 2 | 0.0 |
DNA | 3 | 0.0 |
Sequence Analysis | 2 | 0.0 |
Genetic Markers/genetics | 7 | 1.0 |
*Psychotropic Drugs | 3 | 75.0 |
*Street Drugs | 3 | 75.0 |
Chromosomes, Human, Pair 1 | 2 | 0.0 |
Neuropsychological Tests | 2 | 0.0 |
Cell Adhesion Molecules, Neuronal/*genetics | 2 | 7.0 |
Genes, Structural | 3 | 0.0 |
Substance-Related Disorders/genetics/physiopathology | 2 | 66.0 |
*Point Mutation | 3 | 0.0 |
DNA-Directed DNA Polymerase/*genetics | 2 | 7.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Internal-External Control | 2 | 18.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Tourette Syndrome/diagnosis/*genetics | 2 | 66.0 |
Substance-Related Disorders/*genetics/rehabilitation | 2 | 100.0 |
France | 2 | 0.0 |
Ataxia Telangiectasia/*genetics | 3 | 4.0 |
African Continental Ancestry Group | 2 | 0.0 |
Genome, Human | 2 | 0.0 |
Genetic Predisposition to Disease/epidemiology | 2 | 2.0 |
Receptors, Dopamine D2 | 9 | 60.0 |
Mutation/genetics | 2 | 0.0 |
Oligodeoxyribonucleotides/genetics | 2 | 2.0 |
DNA/isolation & purification | 2 | 1.0 |
Schizophrenia/drug therapy/genetics | 2 | 50.0 |
Italy/epidemiology | 2 | 0.0 |
Receptors, Muscarinic/*immunology | 2 | 100.0 |
Protein Biosynthesis | 2 | 0.0 |
Antipsychotic Agents/*adverse effects/therapeutic use | 2 | 16.0 |
Dyskinesia, Drug-Induced/etiology/*genetics | 2 | 66.0 |
Neuroleptic Malignant Syndrome/*genetics | 2 | 66.0 |